Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 12:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 47 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 2 Interventional Results available

Pioglitazone in Early Parkinson's Disease

NCT01280123
Conditions
Parkinson's Disease
Interventions
Pioglitazone, placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
30 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 32 more
Conditions
Early Parkinson Disease
Interventions
K0706, placebo
Drug · Other
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
50 Years and older
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 30 more
Completed Phase 3 Interventional Results available

Efficacy of Isradipine in Early Parkinson Disease

NCT02168842
Conditions
Parkinson Disease
Interventions
Isradipine, Placebo (for Isradipine)
Drug
Lead sponsor
University of Rochester
Other
Eligibility
30 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
47
States / cities
Birmingham, Alabama • Sun City, Arizona • Fountain Valley, California + 40 more
Conditions
Parkinson Disease
Interventions
Physical Activity Coaching
Behavioral
Lead sponsor
Teachers College, Columbia University
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
New York, New York
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Neuroplasticity in Parkinson's Disease

NCT05286736
Conditions
Parkinson, Parkinson Disease
Interventions
Neuroimaging, Quantitative assessments
Diagnostic Test
Lead sponsor
University of Minnesota
Other
Eligibility
21 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Early Stage Parkinson's Disease
Interventions
Pardoprunox, Placebo
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
24
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Fountain Valley, California + 20 more
Conditions
Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic
Interventions
NEU-411, Placebo
Drug · Other
Lead sponsor
Neuron23 Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
45
States / cities
Sun City, Arizona • Little Rock, Arkansas • Fresno, California + 40 more
Conditions
Parkinson's Disease
Interventions
Inosine, Placebo
Drug
Lead sponsor
Michael Alan Schwarzschild
Other
Eligibility
30 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
61
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 51 more
Conditions
Parkinson Disease
Interventions
BHV-8000 10mg, BHV-8000 20 mg, Placebo
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
40 Years to 80 Years
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Farmington, Connecticut + 12 more
Conditions
Parkinson's Disease
Interventions
venglustat GZ/SAR402671, Placebo
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
19
States / cities
Scottsdale, Arizona • La Jolla, California • Palo Alto, California + 10 more
Conditions
Parkinson Disease, Early Parkinson's Disease
Interventions
P2B001 0.6/0.75 mg, Rasagiline 0.75 mg, Pramipexole 0.6 mg, Marketed Pramipexole ER
Drug
Lead sponsor
Pharma Two B Ltd.
Industry
Eligibility
35 Years to 80 Years
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
45
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 39 more
Conditions
Parkinson Disease
Interventions
sumanirole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years and older
Enrollment
854 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
69
States / cities
Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 60 more
Conditions
Idiopathic Parkinson Disease
Interventions
VTX3232
Drug
Lead sponsor
Zomagen Biosciences Ltd.
Industry
Eligibility
40 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Early-Stage Parkinson's Disease
Interventions
Rotigotine
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
31 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
37
States / cities
Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 34 more
Conditions
Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline, Alzheimer's Disease Dementia, Alzheimer's Disease Diagnosis, Alzheimer's Disease and Related Dementias, Parkinson's Disease, Parkinson's Disease (PD), Parkinson's Disease With Wearing-off Motor Fluctuations, Dementia (Diagnosis), Dementia MCI (Mild Cognitive Impairment)
Interventions
Structured wellness care, Wearable brain-computer interface devices, Stem Cell Therapy - Experimental, Control - Placebo Comparator
Behavioral · Device · Biological + 1 more
Lead sponsor
Noah Tech, Corp.
Industry
Eligibility
55 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Palisades Park, New Jersey
Completed Phase 3 Interventional Results available

Flexible-Dose Trial in Early Parkinson's Disease (PD)

NCT04223193
Conditions
Parkinson Disease
Interventions
Tavapadon, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
40 Years to 80 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
18
States / cities
Fresno, California • Boca Raton, Florida • Maitland, Florida + 14 more
Conditions
Parkinson's Disease, Healthy
Interventions
BIIB054, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
40 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
9
States / cities
Washington D.C., District of Columbia • Hallandale, Florida • Oviedo, Florida + 6 more
Conditions
Early Stage Parkinson's Disease
Interventions
Pardoprunox
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
25
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Fountain Valley, California + 21 more
Conditions
Parkinson Disease
Interventions
NLY01, Vehicle
Drug
Lead sponsor
Neuraly, Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
60
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 49 more
Conditions
Parkinson's Disease
Interventions
CVT-301, LIP, Placebo
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
30 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
11
States / cities
Fountain Valley, California • Boca Raton, Florida • Hallandale, Florida + 8 more
Conditions
Parkinson's Disease
Interventions
ROTIGOTINE
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 99 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
3
States / cities
Long Beach, California • Hallandale, Florida • Atlanta, Georgia
Conditions
Parkinson's Disease
Interventions
Rotigotine, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
7
States / cities
Reseda, California • Ventura, California • St. Petersburg, Florida + 4 more
Conditions
Parkinson's Disease
Interventions
P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),, Placebo, P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),
Drug
Lead sponsor
Pharma Two B Ltd.
Industry
Eligibility
35 Years to 75 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 21 more
Conditions
Parkinson's Disease
Interventions
PYM50028, Placebo
Drug
Lead sponsor
Phytopharm
Industry
Eligibility
35 Years to 75 Years
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
41
States / cities
Scottsdale, Arizona • Irvine, California • La Jolla, California + 37 more